<h4>Background</h4>Limited real-world data exist on the effectiveness of treatment intensification (TI) with androgen receptor pathway inhibitors (ARPI) in de novo metastatic castration-sensitive prostate cancer (mCSPC). The gene discussed is AR; the disease is prostate carcinoma.